Stand Up Therapeutics Co Ltd had signed an agreement with VectorBuilder Inc, a provider of gene delivery solutions, to manufacture a GMP-grade gene therapy system to treat paralysis.

Stand Up Therapeutics, based in South Korea, is a gene therapy company for paralyzed patients with spinal cord injury.

Through this agreement, VectorBuilder will produce and supply gene therapy products designed by Stand Up Therapeutics in the future.

VectorBuilder’s Chief Scientist Bruce Lahn said, “VectorBuilder is very interested in Stand Up Therapeutics’s gene therapy for the treatment of paralysis at the global level. As a world leader in the design and GMP manufacturing of gene delivery vectors, I hope it would be a good opportunity for VectorBuilder to supply this product to Stand Up for patients worldwide.”

Stand Up Therapeutics CEO Dr. Junsang Yoo said, “Stand Up Therapeutics is the only one in the world that has the technology that treats paralyzed patients due to spinal cord injury using own developed direct lineage reprogramming technology (STUP-001). Members of Stand Up Therapeutics is putting full efforts in developing a treatment for patients suffering from paralysis due to traumatic injury.”

“With the direct cross-differentiation PIPELINE technology, Stand Up Therapeutics plans to develop treatments for Parkinson’s disease (STUP-002), stroke (STUP-003), spinal stenosis (STUP-004) and myocardial infarction (STUP-005) in the future,” he adds.

For STUP-001, the spinal cord injury (SCI) gene therapy treatment, they are getting into IIT Clinical phase I/IIa study in 2023 1Q with four paraplegia patients.

[Source(s): Stand Up Therapeutics Co Ltd, PR Newswire]

Related Content:
Gene Therapy Shows Promise in Treating Neuropathy from Spinal Cord Injuries